<DOC>
	<DOCNO>NCT02255617</DOCNO>
	<brief_summary>The purpose study determine FMT reverse Hepatic Encephlopathy ( HE ) cirrhotic patient continue breakthrough episode HE despite maintenance therapy lactulose and/or rifaximin metronidazole .</brief_summary>
	<brief_title>Fecal Microbiota Transplantation ( FMT ) Management Hepatic Encephalopathy ( HE ) : Pilot Study</brief_title>
	<detailed_description>Subjects receive FMT single donor colonoscopy Week 0 enema Weeks 1-4 . HE measure Inhibitory Control Test Stroop well serum ammonia level .</detailed_description>
	<mesh_term>Brain Diseases</mesh_term>
	<mesh_term>Hepatic Encephalopathy</mesh_term>
	<criteria>1. adult ( age &gt; 18 year age ) cirrhotic patient various etiology , lactulose and/or rifaximin flagyl least 4 week secondary prophylaxis 2. abnormal inhibitory control test , define great 5 lure . 3. infectious etiology may cause HE rule 1. tense ascites 2. provide assent 3. judged life expectancy le 3 month , 4. TIPS within 3 month , 5. neurologic disease dementia , Parkinson 's disease , structural brain lesion 6. pregnancy 7. intestinal obstruction 8. alcoholic hepatitis 9. active alcohol substance abuse 10. without stable social support 11. concurrent infection , SBP , pneumonia UTI 12. creatinine clearance le 50 % compare baseline 13. recent hospital admission , define within one month enrollment , hepatic encephalopathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>